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Breast core needle biopsy (CNB) is an accurate test but may result in borderline histology (lesions of uncertain malignant potential or
B3). This is an evaluation of the largest series (to date) of B3 histology, which focusses on estimating positive predictive values (PPV)
for malignancy. We identified all B3 CNBs over a 10-year period in a single institution (N¼372) from a series of 4035 consecutive
needle biopsies. We describe the imaging findings, and report excision histology outcomes (N¼279) and category-specific PPV for
B3 lesions using two approaches including estimates based on subjects who had either excision or follow-up (N¼328). B3
represented 9.2% of all CNB results. Excision histology was benign in 181 (64.9%) and malignant in 98 (35.1%) subjects (61 ductal
carcinoma in situ, 37 invasive carcinoma). Positive predictive value for malignancy (based on excision histology) was 35.1% (95% CI:
29.5–40.7) and PPV (based on excision or review) was 29.9% (95% CI: 24.9–34.8). Lesion-specific PPV (estimates in parentheses for
excision or follow-up) was atypical ductal hyperplasia 44.7% (40.6%); lobular intraepithelial neoplasia 60.9% (58.3%); papillary lesion
22.7% (15.9%); radial scar 16.7% (12.3%); phyllodes tumour 12.5% (12.5%); and B3 not specified 20.0%. Approximately one-third of
CNB results classified as B3 are malignant on excision, and the likelihood of malignancy varies substantially between specific lesion
groups. Whereas cases may be selectively managed without surgery, the majority warrant excision biopsy based on our estimates.
Research is needed to improve differentiation between malignant and benign diseases in B3 lesions using diagnostic or predictive
methods.
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Percutaneous core needle biopsy (CNB) is an accurate test for
sampling breast lesions (Parker et al, 1994; Burbank, 1997;
Liberman, 2000; Ciatto et al, 2006) and is increasingly replacing
fine needle aspiration cytology (FNAC) in breast diagnosis. Core
needle biopsy has advantages over FNAC in that it provides
histological information, which improves sensitivity and may
assist pre-operative treatment planning (Houssami et al, 2006),
and is rarely associated with inadequacy (insufficiency) (Ciatto
et al, 2006). It also has a complementary role to FNAC where FNAC
is used as an initial test and where the cytology is atypical
(Bulgaresi et al, 2006) – subsequent use of CNB in this context can
establish a definitive diagnosis. The major limitation that has
emerged with CNB is the borderline histology spectrum, a
heterogeneous group of lesions also described as lesions of
uncertain malignant potential (B3 core histology) in international
standards (NHS Non-operative Diagnosis Subgroup of the
National Coordination Group for Breast Screening Pathology,
2001; Perry et al, 2006).
Despite the current perspective that CNB has better diagnostic
discrimination between benign and malignant breast disease than
FNAC, borderline (B3) core needle histology occurs in a similar
(Lee et al, 2003) or higher proportion of cases as does atypical or
borderline cytology (when considered within the same institu-
tional context) (Ciatto et al, 1993; Lee et al, 2003; Ciatto et al,
2006). Borderline (B3) core needle histology, however, has more
significant implications in that most cases progress to surgical
intervention, and debate continues on whether selected cases may
be spared excision (Jacobs et al, 2002). While most cases of B3
CNB will in fact have benign disease, approximately one-quarter
(Lee et al, 2003) or more will have cancer on excision; however,
estimates of the proportion with malignancy on excision biopsy
are based on small series (Jacobs et al, 2002).
We present a retrospective evaluation of the largest series, to
date, of borderline (B3) core needle histology, and report on
excision histology outcomes. We provide B3 (lesions of uncertain
malignant potential) subcategory-specific positive predictive
values (PPV) for malignancy (in situ and invasive), and discuss
implications for practice and future research.
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sMATERIALS AND METHODS
From all subjects who attended the study centre between January
1996 and March 2005, and had a core biopsy of any type (4035
biopsies), we identified eligible subjects as all those with B3 core
histology reports (N¼372). We have included all eligible cases in
our descriptive evaluation, and for histological outcomes we report
on subjects who had excision histology (N¼279). To avoid
verification bias in estimating category-specific PPV (Houssami
and Irwig, 1998), we have retained in the PPV analysis all eligible
subjects who had either excision histology or at least one episode
of follow-up (N¼328). Imaging lesions were considered stable on
follow-up if unchanged on imaging (and clinical) review at 6–12
months (for masses) or a minimum of 12 months (for
microcalcification) (Ciatto et al, 2006).
Detailed methodology of all consecutive core biopsies,
from which this series of borderline core needle histology
originated, has been published in our companion paper (Ciatto
et al, 2006). In brief, CNB was performed over the timeframe
of the study by one of 13 radiologists who also performed the
clinical examination. Core needle biopsy was used for imaging
lesions that were atypical or associated with some degree
of suspicion. At the study centre, BI-RADS is not routinely used
for reporting imaging, an alternate classification is used with
published estimates of the likelihood of malignancy (Houssami
and Irwig, 1998). Most lesions in this series were therefore imaging
categories 3–5 (3 – indeterminate, 4 – suspicious and 5 –
malignant) (Houssami and Irwig, 1998). Core needle biopsy in
the study centre was generally performed using conventional
automated (14 G) core needle for sampling masses, whereas
microcalcifications were preferentially sampled using vacuum-
assisted biopsy (11G) and less often using automated (14 G) core
(Ciatto et al, 2006). Stereotactic sampling of microcalcification was
verified with specimen X-ray. Ultrasound guidance was preferen-
tially used for all lesions clearly seen on ultrasound and also for
masses (including where palpable), and the use of stereotaxis was
largely for microcalcification and impalpable mammographic
lesions.
One of two breast pathologists reported all core needle histology
(without knowledge of outcomes), with one pathologist (SB)
interpreting the vast majority (490%). Results were reported
in line with UK and European guidelines (NHS Non-operative
Diagnosis Subgroup of the National Coordination Group
for Breast Screening Pathology, 2001; Perry et al, 2006). Categories
are B1¼normal tissue/unsatisfactory, B2¼benign, B3¼lesions
of uncertain malignant potential, B4¼suspicious of malignancy,
B5 (malignant–sub-classified as ductal carcinoma in situ
(DCIS) or invasive cancer) (NHS Non-operative Diagnosis
Subgroup of the National Coordination Group for Breast Screening
Pathology, 2001; Perry et al, 2006). The borderline histology
or B3 category includes atypical ductal hyperplasia (ADH), lobular
intraepithelial neoplasia (LIN) (regrouping of the former atypical
lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS)),
papillary lesions, radial scar/complex sclerosing lesion, mucocoele-
like lesion and phyllodes tumour.
We describe the distribution of outcomes, the type of imaging
lesion and whether clinically palpable, in all subjects. We
also provide a descriptive analysis of imaging findings for
all subjects according to B3 groups and in relation to outcomes
to provide clinical context. Excision histology findings are
reported for benign and malignant outcomes, and PPVs
are calculated for all B3 core histology and for each subcategory.
We have estimated PPVs using two approaches, one based
on all cases verified with excision histology and also cases
shown to have remained stable on review (this minimises
verification bias in estimating measures of accuracy) (Houssami
and Irwig, 1998). We have also calculated them using the more
conventional approach of including only those verified with
excision histology.
RESULTS
B3 core needle histology comprised 9.2% 372 from 4035 of all
CNB results. To assist in judging generalisability of our series,
we have presented in Table 1 the distribution of all B3 cases
according to type of lesion depicted on mammography,
excision histology or other outcomes and palpability. Microcalci-
fication (46%) and masses (44.6%) were about equally distributed,
and distortions represented 9.4% of lesions assessed with CNB.
Imaging lesions were clinically palpable in 27.4% of cases,
and 72.6% were considered impalpable (Table 1), reflecting the
high frequency of isolated microcalcification evaluated with
CNB (all of which were impalpable). Data in Table 1 included
six cases of suspicious (B3–B4) results, which on further review
were considered to represent B4, and were therefore excluded
from our analysis of PPV – all six cases were found to represent
malignancy (one DCIS, five invasive cancers). A detailed
distribution of all B3 core needle histology cases according
to the type of lesion depicted on imaging and the level of
suspicion on imaging, in relation to outcomes, is included as
Appendix A.
Table 2 summarises all excision histology outcomes for B3 core
needle histology, overall and for each subcategory of B3, and
presents category-specific PPV. Overall, PPV for malignancy
(based on excision histology) was 35.1% (95% CI: 29.5–40.7)
and PPV (based on excision or review) was 29.9% (95% CI: 24.9–
34.8). There were five cases of B3 not otherwise specified based on
the original pathology report (Table 2). These were subsequently
reviewed and were classified as B3 phyllodes, B3 ADH/columnar
cell lesion, B3 fibromatosis or phyllodes, B3 granular cell tumour
and B2 fibroadenolipoma.
Table 1 Distribution of B3 (lesions of uncertain malignant potential) core needle histology (N¼372): type of lesion depicted on mammography,
outcomes and palpability
Lesion type on
mammography
Excision histology outcome (N¼285)
a Lesions not excised
Total (number palpable)
c Benign
Atypical
hyperplasias
b DCIS
Invasive
cancer
Stable on
review
Pending
review
Mass (or density) 53 31 15 20 31 16 166 (98)
Distortion 21 3 1 3 5 2 35 (4)
Microcalcification 39 34 46 19 13 20 171 (0)
Total number 113 68 62 42 49 38 372 (102)
DCIS¼ductal carcinoma in situ.
aThis included six cases of suspicious CNB results (retained only for descriptive analysis).
b‘Atypical hyperplasias’ included atypical ductal
hyperplasia and lobular intraepithelial neoplasia (lesions associated with increased future risk of breast cancer).
cNumber palpable¼number of lesions from total (and for each
type of mammographic lesion) considered to be evident on clinical examination.
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sDISCUSSION
We have reported B3 (borderline lesions or lesions of uncertain
malignant potential) category-specific PPV for malignancy (DCIS
and invasive); B3 core needle histology comprised about 9% of all
consecutive CNB performed in the study centre. We are not aware
of any published work that estimates PPV for subcategories of B3
lesions in one comprehensive series. Overall, about one-third of
borderline lesions on CNB in this study proved to be malignant
(PPV 29.9 or 35.1%); however, the PPV for each subcategory
within B3 varied substantially (Table 2). In an overview of this
topic, Jacobs et al (2002) reported that knowledge and consensus
on the management of these lesions are hindered by the very small
number of subjects in most studies, and also by selection bias for
subjects managed with excision biopsy (Jacobs et al, 2002).
Whereas acknowledging that a few studies have included more
cases per specific B3 lesion (Cawson et al, 2003; Shah et al, 2006),
we believe that our study addresses the first issue in providing
the largest consecutive study of B3 cases. As for the latter issue,
and while selection to surgery was not entirely avoided, the vast
majority of subjects had excision in our series. We have also
included outcomes for some of the subjects that did not have
surgery, and overall, we have reported outcomes in approximately
88% of subjects.
We have explained the reasons we report two estimates of PPV –
methodologies that include all subjects with known outcomes (and
not only those verified on the basis of excision) have been shown
to reduce verification bias in calculating measures of accuracy
(Houssami and Irwig, 1998), whereas subjects with outcomes
verified on the basis of excision histology are traditionally included
to avoid misclassification. We have provided estimates of PPV
using both methods, and acknowledge the limitation of length of
follow-up in the minority group that had follow-up only in our
series. It should be noted that the proportion of CNB reported to
be B3 and the distribution of lesion categories within the
borderline CNB spectrum will vary between institutions, as this
is dependent on the criteria used for reporting as well as the
number of pathologists involved in reporting and their threshold
for classifying a lesion as borderline on CNB. We also point out
that overall and lesion-specific predictive values may vary in
different settings according to the type of imaging abnormalities
assessed with CNB and the sampling methods used; we have
described the study centre’s practice in this paper and in our
related paper (Ciatto et al, 2006), and the data in Appendix A
provide detailed imaging context for the series.
Lee et al (2003) provide data on histological outcomes for the
B3 category in 96 excised lesions, and report an overall PPV
of 26% for B3 CNB histology that is slightly lower than our
overall estimates. These authors make the point that excision
biopsy findings for B3 are heterogeneous, that the clinical
and radiological features are important in deciding further
management (and that this should be carried out in multi-
disciplinary meetings). We agree with these views, and our
work highlights the heterogeneity of the borderline or B3 CNB
category, in addition to evidence on lesion-related variability in
likelihood of malignancy as an outcome in B3 cases. Clearly,
lesions categorised on CNB as ADH (more appropriately
termed atypical intraductal epithelial proliferation on CNB
histology), or as LIN, are associated with a significantly higher
probability of cancer as an outcome relative to the ‘other’
borderline lesions. It may be worthwhile reconsidering current
categorisation criteria (NHS Non-operative Diagnosis Subgroup of
the National Coordination Group for Breast Screening Pathology,
2001; Perry et al, 2006) and potentially modifying the B3 category
into two risk-based subgroups (B3 with lower probability of
cancer, B3 with higher probability of cancer). This would be
expected to improve specificity and may assist management
decisions in the context of team discussion.
The most frequent lesion in our B3 series is ADH, and its
frequency within the B3 category is similar to that reported by Lee
et al (2003). The PPV for ADH (44.7 or 40.6%) is also similar to
other studies (Jackman et al, 1999; Harvey et al, 2002; Lee et al,
2003), although we have reported estimates based on a larger
number of cases. This estimate further emphasises that the
standard of care for lesions yielding ADH on CNB should be
excision biopsy.
Our PPV estimates show the highest lesion-specific risk of
malignancy in association with LIN (ALH and LCIS) with a higher
likelihood of malignancy for this category than reported in other
series (Lee et al, 2003; Elsheikh and Silverman, 2005). The evidence
on, and the management of, lobular neoplasia continues to be
contradictory and controversial (Lakhani et al, 2006) and a
detailed discussion of this lesion category is beyond the scope of
this paper. The largest published series that examined pure lobular
neoplasia (based on 33 subjects) emphasised that all CNB
diagnoses of ALH and LCIS warrant surgical excision because of
a high risk of malignancy on excision histology (Elsheikh and
Silverman, 2005). We also point out that most other series of
lobular neoplasia on CNB have been based on very few subjects
with many subjects not progressing to excision biopsy (Jacobs
Table 2 Lesions of uncertain malignant potential (B3) on CNB: excision histology outcomes for different B3 lesions and associated PPV for breast
malignancy
Subcategory of B3 core
needle histology (number
of cases with excision
outcomes)
Benign on excision histology
Invasive
cancer DCIS
PPV % (excision or
review)
b
PPV % (excision
histology)
c
Number (% of all
excised lesions)
Number with concordant
histology (number
upstaged to a high risk
lesion
a)
ADH
d (141) 78 (55.3) 42 (NA) 21 42 40.6 (63/155) 44.7 (63/141)
LIN (23) 9 (39.1) 3 (NA) 2 12 58.3 (14/24) 60.9 (14/23)
Papillary lesion (44) 34 (77.3) 7 (6) 7 3 15.9 (10/63) 22.7 (10/44)
Radial scar (42) 35 (83.3) 15 (5) 3 4 12.3 (7/57) 16.7 (7/42)
Phyllodes tumour (24) 21 (87.5) 16 (0) 3 0 12.5 (3/24) 12.5 (3/24)
B3 (not otherwise specified) (5) 4 (80.0) NA (0) 1 0 20.0 (1/5) 20.0 (1/5)
All B3 categories (279) 181 (64.9) 83 (11) 37 61 29.9 (98/328) 35.1 (98/279)
ADH¼atypical ductal hyperplasia; DCIS¼ductal carcinoma in situ; LIN¼lobular intraepithelial neoplasia; NA¼not applicable; PPV¼positive predictive values.
aWhere excision
histology specifies ADH or lobular neoplasia (lesions with known long-term risk of breast cancer) as the dominant lesion.
bPPV based on all cases verified with excision histology
and cases shown to have remained stable on follow-up (N¼328).
cPPV based on all cases verified with excision histology (N¼279).
dADH on CNB is more appropriately
described as atypical intraductal epithelial proliferation.
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set al, 2002). The vast majority of cases of lobular neoplasia on CNB
in our series were managed with surgery and most were shown to
have DCIS on excision histology – since many of the CNBs were
performed for imaging lesions, some of our cases are likely to have
represented under-sampling of the target lesion. It is particularly
important that CNB reports of LIN be correlated with the clinical
and imaging findings, and that management decisions are decided
on the basis of team discussion (Lee et al, 2003; Lakhani et al,
2006).
Unlike our PPV for papillary lesions (22.7 or 15.9%), one study
of screen-detected papillary lesions reported benign excision
histology outcomes in all 15 CNB diagnoses of ‘papillary lesion’
classified as B3 (Carder et al, 2005). Liberman et al (2006)
evaluated 35 cases with a diagnosis of (benign) papilloma on CNB
(and concordant with imaging), and reported a cancer yield of 14%
(based on either surgery or follow-up), which is similar to our PPV
for papillary lesion on CNB (based on either surgery or follow-up).
A review by Jacobs et al (2002) reported malignancy as an outcome
following a CNB diagnosis of papillary lesion (without atypia)
ranging between 0 and 25%. Shah et al (2006) reported improved
accuracy for categorising benign papillary lesions on CNB by using
immunohistochemistry. Variability in reported estimates for this
lesion (and other lesions in the borderline category) may be due to
a combination of factors as we have already discussed, including
the proportion of subjects with verified outcomes, selection of
imaging lesions assessed with core biopsy, study sample size and
pathology reporting methods.
The lesions with the lowest PPV for malignancy in our study are
phyllodes tumour and radial scar. The recommended management
of both these lesions is surgical excision to differentiate phyllodes
tumour from fibroadenoma in the former and to exclude
associated malignancy in the latter. Research efforts might
particularly target lesions with a lower PPV for malignancy in
exploring selective non-surgical management. Because of the
timeframe of our study, columnar cell lesions were not included
as a separate category; however, the potential importance of
columnar cell lesions and columnar cell atypia in predicting
malignancy is another area for future research.
We have described the histology in lesions with benign
outcomes on excision – these data show moderate concordance
between the specific benign histology reported on CNB and
excision biopsy, and we have included the number of cases
upgraded to lesions with increased future risk of breast cancer.
It would be reasonable to argue that such distinctions within the
benign pathology spectrum are of limited clinical relevance, but we
have provided the information to be comprehensive as this may be
relevant to clinicians providing care and surveillance advice to
women with benign breast disease.
Our work emphasises the heterogeneity of lesions of uncertain
malignant potential (B3) as far as risk of malignancy. Research is
needed to help modify our current approach of surgical manage-
ment for almost all borderline core needle histology, thus
minimising unnecessary surgery in the majority of women with
B3 on CNB and have benign disease. One example is optimising
criteria for reporting lesions as B3 on CNB – pathologists might
work on characterisation of morphological features that potentially
allow accurate shifting of some B3 lesions into either the benign or
the malignant category. Another area in need of formal evaluation
is the selective use of large (vacuum-assisted) core biopsy devices
in lesions deemed to be low risk (low PPV) on CNB to either re-
sample or remove the imaging lesion, as an alternate to surgical
excision. This should only be performed in the context of
radiology–pathology correlation and team discussion to ensure
appropriate selection of low risk lesions for this form of
management.
The most relevant research, however, is likely to be in
potentially identifying factors or methods that accurately predict
outcomes on excision histology for the spectrum of B3 lesions.
This may be achieved through two approaches, the first being the
evaluation of molecular or genetic markers as indicators of
malignancy. Although genetic profiling has indicated that current
histological classification of breast cancer does not predict either
lymph node metastases or response to therapy, it remains possible
that the combination of genetic profile and core needle histology
could provide a new diagnostic modality with the greatest
discriminatory ability for outcomes. The second approach is the
development of predictive systems based on clinical–radiologi-
cal–CNB correlates with excision histology. We are currently
exploring the latter of these approaches.
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(38))
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d (n¼181)
Malignant (DCIS and invasive
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(N¼172) D¼3 (IM3¼1, IM4¼2) D¼1 (IM4¼1) D¼3 (IM3¼3)
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C¼4 (IM3¼2, IM4¼2) C¼10 (IM3¼6, IM4¼4) C¼4 (IM3¼1, IM4¼3)
Papillary lesion M¼26 (IM3¼20, IM4¼6) M¼7 (IM3¼6, IM4¼1) M¼22 (IM3¼18, IM4¼4)
(N¼70) D¼0D ¼0C ¼4 (IM3¼3, IM4¼1)
C¼8 (IM3¼6, IM4¼2) C¼3 (IM3¼1, IM4¼2)
Radial scar M¼12 (IM3¼4, IM4¼7, IM5¼1) M¼3 (IM3¼1, IM4¼2) M¼15 (IM3¼6, IM4¼9)
(N¼63) D¼19 (IM3¼12, IM4¼7) D¼2 (IM4¼2) D¼4 (IM3¼3, IM4¼1)
C¼4 (IM3¼3, IM4¼1) C¼2 (IM3¼1, IM4¼1) C¼2 (IM4¼2)
Phyllodes tumour M¼21 (IM3¼20, IM4¼1) M¼3 (IM3¼3) M¼1 (IM3¼1)
(N¼25) D¼0D ¼0D ¼0
C¼0C ¼0C ¼0
B3 (not otherwise specified) M¼2 (IM3¼2) M ¼1 (IM4¼1) M¼1 (IM3¼1)
(N¼7) D¼0D ¼0D ¼0
C¼2 (IM4¼2) C¼0C ¼1 (IM4¼1)
Categorised as suspicious M¼0M ¼5 (IM3¼4, IM4¼1) M¼0
(B4)
c on review D¼0D ¼1 (IM4¼1) D¼0
(N¼6) C¼0C ¼0C ¼0
All categories M¼83 (IM3¼58, IM4¼24, IM5¼1) M¼37 (IM3¼21, IM4¼13, IM5¼3) M¼46 (IM3¼33, IM4¼13)
(N¼372) D¼25 (IM3¼14, IM4¼11) D¼4 (IM3¼4) D¼7 (IM3¼6, IM4¼1)
C¼73 (IM3¼33, IM4¼38, IM5¼2) C¼63 (IM3¼27, IM4¼33, IM5¼3) C¼34 (IM3¼13, IM4¼20, IM5¼1)
ADH¼atypical ductal hyperplasia; LIN¼lobular intraepithelial neoplasia.
aType of lesion depicted on imaging: M¼mass (or density), D¼distortion, C¼microcalcacification.
bLevel of suspicion on imaging (IM) using categories 1–5 (Houssami and Irwig, 1998) based on mammography classification, or on ultrasound classification where mammography
was not carried out or was negative.
cSix cases were classified as suspicious CNB results on further review (retained only for descriptive analysis).
d‘Atypical hyperplasias’ on
excision histology included ADH and LIN (lesions associated with increased future risk of breast cancer).
Borderline (B3) breast core needle histology
N Houssami et al
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